Description: Stayble Therapeutics AB (publ) develops injectable treatment for chronic pain triggered by disc degeneration. The company develops STA363, an injection into the disc that targets chronic low back and leg pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
Home Page: www.staybletherapeutics.se
Lennart Torstenssonsgatan 6
Gothenburg,
412 56
Sweden
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Andreas Gerward M.Sc. | Co-Founder & CEO |
| Mr. Mattias Munnich M.Sc. | Co-Founder |
| Mr. Erik Kullgren | Chief Financial Officer |
| Mr. Anders Lehmann Ph.D. | Chief Scientific Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.9108 |
| Price-to-Sales TTM: | 744.4416 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |